Recent 8-K filings for LYRA
Highest-materiality recent filing
Nasdaq notifies Lyra Therapeutics of delisting; company deemed a public shell
- Nasdaq cites public shell status after suspension of lead drug LYR-210 and near-complete workforce reduction.
- Nasdaq also cites non-compliance with minimum $2.5M equity listing rule.
-
Lyra Therapeutics terminates Waltham sublease; pays $2.1M termination fee
Termination of sublease for 23,704 sq ft at 880 Winter Street, Waltham, MA, effective March 31, 2026.
-
Lyra Therapeutics terminates two leases, forfeits $1.4M deposits and pays $2.5M in fees
Watertown lease (22,343 SF): forfeits $302,514.84 LC deposit + pays $1M modification; lease ends May 31, 2026.
-
Lyra Therapeutics to suspend trading on Nasdaq March 17 after delisting appeal withdrawal
Company withdrew appeal of February 2, 2026 Nasdaq delisting determination.
-
Lyra Therapeutics receives default notice for $484K unpaid rent; wind-down continues
Received default notice from sublessor RVAC on Feb 23, 2026 for unpaid rent at Waltham office.
-
Nasdaq notifies Lyra Therapeutics of delisting; company deemed a public shell
Nasdaq cites public shell status after suspension of lead drug LYR-210 and near-complete workforce reduction.
-
Lyra suspends LYR-210 development, lays off nearly all staff; CEO/CFO become consultants
Board approved plan to suspend LYR-210 development and reduce workforce affecting substantially all employees, effective Jan 12, 2026.
-
Lyra Therapeutics reports Q3 net loss $6.0M, plans new Phase 3 trial for LYR-210
Cash and cash equivalents $22.1M at Sep 30, 2025; cash runway into Q3 2026.
-
Lyra Therapeutics receives Nasdaq deficiency notice for equity below $2.5M minimum
Stockholders' equity as of June 30, 2025 was ~$1.6M, below the $2.5M continued listing requirement.
-
Lyra Therapeutics Q2 2025 net loss $7.4M; cash $29.8M; ENLIGHTEN 2 Phase 3 met primary endpoint
Net loss Q2 2025 $7.4M vs $48.1M YoY due to lower R&D and no impairment charges.
-
Lyra Therapeutics raises $5M upfront (up to $15M with warrant exercise) in equity offering
Upfront gross proceeds of $5.0M from sale of 423,372 shares (or pre-funded warrants) at $11.81 per share+private warrant.
-
ENLIGHTEN 2 met primary endpoint: LYR-210 improved 3CS composite score vs sham at 24 weeks (-1.13, p=0.0078) in non-polyp patients.
-
Lyra Therapeutics approves 1-for-50 reverse stock split, effective May 27
Stockholders approved reverse-split authority at 1-for-10 to 1-for-50 range; Board set final ratio at 1-for-50.
-
Lyra Therapeutics reports Q1 net loss of $8.5M; ENLIGHTEN 2 top-line results expected Q2 2025
Net loss of $8.5M ($0.13 per share) vs. $22.5M ($0.35) in Q1 2024; cash burn reduced YoY.
-
Lyra Therapeutics reports FY2024 net loss $93.4M; ENLIGHTEN 2 top-line data expected Q2 2025
Net loss for FY2024 was $93.4M ($1.43 diluted EPS) vs $62.7M in FY2023; cash $40.6M as of Dec 31, 2024.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.95 · Median 0.70 · Most common event other_material